Olalekan Oluwole is an Oncology physician affiliated with Vanderbilt University. OpenAlex indexes 378 publications with 20,903 citations (h-index 49); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320028
Telephone
615-322-3000Provider last certified this registry record 28 Mar 2022.
Clinical trials
- Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Sponsor: Vanderbilt-Ingram Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202523 payments$51,219openpaymentsdata.cms.gov ↗
- Kite Pharma, Inc.Program year202515 payments$26,777openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
46.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor26.4%Valacyclovir100%Part D≥33 patientsAzole Antifungal7%Fluconazole100%Part D≥18 patients+ 3 more classes in this area
Cancer & immunology
15%Kinase inhibitor15%Calquence57%Brukinsa43%Part D<11 patientsMetabolism & gastrointestinal
12.3%Serotonin-3 Receptor Antagonist7.3%Ondansetron Hcl100%Part D≥22 patientsProton pump inhibitor5%Omeprazole100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology
2024 - NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
James Crowe, MD
Vanderbilt University
Ingrid Mayer, MD
Vanderbilt University
Michael Debaun, MD
Vanderbilt University
Sam Chang, MD
Vanderbilt University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”